AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
292.09B
Market cap292.09B
Price-Earnings ratio
31.14
Price-Earnings ratio31.14
Dividend yield
1.62%
Dividend yield1.62%
Average volume
6.98M
Average volume6.98M
High today
$94.74
High today$94.74
Low today
$94.52
Low today$94.52
Open price
$95.28
Open price$95.28
Volume
14.00K
Volume14.00K
52 Week high
$96.51
52 Week high$96.51
52 Week low
$61.24
52 Week low$61.24

AZN News

Nasdaq 2d
Astrazeneca Ascends While Market Falls: Some Facts to Note

Astrazeneca (AZN) closed at $96.34 in the latest trading session, marking a +1.94% move from the prior day. The stock outperformed the S&P 500, which registered...

Astrazeneca Ascends While Market Falls: Some Facts to Note
TipRanks 2d
AstraZeneca’s Atuliflapon Asthma Trial Reaches Completion: What Investors Should Watch Next

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools...

TipRanks 3d
AstraZeneca Hails AI First as it Snaps Up Modella to Speed Up Cancer Cures

AstraZeneca (AZN) claimed to be the first pharmaceutical company to buy an AI firm today after it snapped up Boston-based Modella AI to speed up the discovery o...

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
9.4%
Sell
9.4%

More AZN News

TipRanks 3d
AstraZeneca Buys Modella AI to Speed Up Cancer Drug Discoveries

Drug giant AstraZeneca (AZN) has bought Boston-based Modella AI to speed up its cancer research work. Claim 70% Off TipRanks Premium The aim is to integrate M...

TipRanks 3d
AstraZeneca put volume heavy and directionally bearish

Bearish flow noted in AstraZeneca (AZN) with 1,393 puts trading, or 1.1x expected. Most active are Jun-26 90 puts and Jan-26 80 calls, with total volume in thos...

TipRanks 3d
AstraZeneca Advances Prostate Cancer Pipeline With New ANDROMEDA Trial on AZD9750

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools...

TipRanks 3d
AstraZeneca Builds Real-World Edge in Rare Neuromuscular Disease With New Russian gMG Study

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools...

TipRanks 4d
AstraZeneca Deepens Respiratory Pipeline With New China-Focused Bronchiectasis Study

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium AstraZeneca (AZN) is sponsoring a new observational stud...

Seeking Alpha 6d
Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20

Walmart (WMT) is set to join the Nasdaq-100 Index before the market opens on Jan. 20, 2026, replacing the Anglo-Swedish pharma giant AstraZeneca (AZN), Nasdaq G...

Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20
Nasdaq 6d
Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle

(RTTNews) - Nasdaq (NDAQ) announced that Walmart Inc. (WMT) will join the Nasdaq-100 Index (NDX), the Nasdaq-100 Equal Weighted Index (NDXE), and the Nasdaq-100...

Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .